6:15 PM
 | 
Dec 18, 2012
 |  BC Extra  |  Clinical News

Actelion's ponesimod meets Phase II psoriasis endpoint

Actelion Ltd. (SIX:ATLN) said induction therapy with once-daily oral ponesimod met the primary endpoint in a Phase II trial to treat moderate to severe chronic plaque psoriasis. Low- and high-dose ponesimod led...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >